Recent Updates
Recently added Catalysts
CRVO

EIP Pharma Announces Phase 2B REVERSE-SD Study of Neflamapimod Fully Enrolled

Thursday, December 13, 2018 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: EIP Pharma Announces Phase 2B REVERSE-SD Study of Neflamapimod Fully Enrolled

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+47%
120-day peak, hindsight
Typical move
6.8%
average across 6 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
Neflamapimod
Phase 2 · Moderate to Severe Acute Ischaemic Stroke

Full Press Release Details

EIP Pharma Announces Phase 2B REVERSE-SD Study of Neflamapimod Fully Enrolled.
ShareAdd on Google
Tags: CRVO Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Dec 13, 2018

Biotech snapshot

Cash runway
$25M liquidity · $2M/mo burn
~10 mo
Medium dilution risk
Lead asset
NeflamapimodPhase 2
Moderate to Severe Acute Ischaemic Stroke →

Catalyst track record

+47%
best trade around CRVO's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CRVO.

See every catalyst's timing & PoA →